Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

1. Simulating an intravenous-to-oral cefotaxime-to-cefditoren/cefuroxime switch: anFrontiers in pharmacology · 2026
   Article
2. Antibiotic susceptibility of pathogens isolated in respiratory tract samples of recently hospitalized patients.Microbiology spectrum · 2025
   Article
3. Exploring therapeutic options for mild diabetic-related foot infections: a comparative in vitro study of cefditoren versus amoxicillin/clavulanic acid.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024
   Article
4. Decalogue for the selection of oral antibiotics for lower respiratory tract infections.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
   Review
5. [Role of cefditoren in the treatment of community skin and soft tissue infections: revisiting the evidence].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021
   Review
6. [Current microbiological aspects of community respiratory infection beyond COVID-19].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2021
   Review
7. [Three keys to the appropriate choice of oral antibiotic treatment in the respiratory tract infections].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract